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ABSTRACT 
The possibility of using genes as medicines to treat brain diseases is currently limited by 
the lack of safe and efficacious delivery systems able to cross the blood-brain barrier, thus 
resulting in a failure to reach the brain after intravenous administration. 
On the basis that iron can effectively reach the brain by using transferrin receptors for 
crossing the blood-brain barrier, we propose to investigate if a transferrin-bearing 
generation 3- polypropylenimine dendrimer would allow the transport of plasmid DNA to 
the brain after intravenous administration. 
In vitro, the conjugation of transferrin to the polypropylenimine dendrimer increased the 
DNA uptake by bEnd.3 murine brain endothelioma cells overexpressing transferrin 
receptors, by about 1.4-fold and 2.3-fold compared to that observed with the non-targeted 
dendriplex and naked DNA. This DNA uptake appeared to be optimal following 2h 
incubation with the treatment.  
In vivo, the intravenous injection of transferrin-bearing dendriplex more than doubled the 
gene expression in the brain compared to the unmodified dendriplex, while decreasing the 
non-specific gene expression in the lung. Gene expression was at least 3-fold higher in the 
brain than in any tested peripheral organs and was at its highest 24h following the injection 
of the treatments.  
These results suggest that transferrin-bearing polypropylenimine dendrimer is a highly 
promising gene delivery system to the brain. 
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1. Introduction 
Gene therapy has emerged as a promising strategy to treat cerebral diseases such as 
glioma, Alzheimer¶V DQG 3DUNLQVRQ¶V GLVHDVHV, which affect a large percentage of the 
ZRUOG¶V population and hardly respond to intravenously administered, small molecule 
treatment [1-4]. Although the genetic basis for many of these diseases is known, the 
possibility of using genes as medicines is currently limited by the lack of safe and 
efficacious delivery systems able to cross the blood-brain barrier (BBB) and to deliver DNA 
to the brain after intravenous administration.  
The BBB acts as an entrance gateway, restricting the movement of ions and nutrients to 
the central nervous system while protecting the brain against harmful blood-borne 
substances and invading organisms [2, 5]. Its permeability properties prevent the delivery 
of more than 98% of drugs, including nucleic acids, to the brain [2, 3]. In addition, locally 
administered treatments fail to achieve a widespread gene expression in the target cells 
throughout the entire brain, which is necessary for a successful treatment of most cerebral 
pathologies [2, 3, 6]. 
However, the BBB does possess specific receptor-mediated transport mechanisms that 
can potentially be exploited as a means to target drugs and genes to the brain. The 
transferrin receptor (TfR) is of particular interest because it is overexpressed on the brain 
capillary endothelial cells [7]. The antibodies that bind to the TfR have been shown to 
selectively target the brain microvascular endothelium due to the high levels of TfR 
expressed by these cells [8-10]. This strategy has been widely investigated for the delivery 
of drugs and genes to the brain [11].  
Several strategies have been explored to formulate TfR-targeted delivery systems able to 
transport nucleic acids to the brain following intravenous administration [11]. Numerous 
non-viral gene delivery systems are currently under development, due to their low 
immunogenicity, stability, unrestricted plasmid size and versatility in types of modifications 
[12, 13]. Among these delivery systems, generation 3- diaminobutyric polypropylenimine 
dendrimer (DAB) appears to be particularly promising. We recently prepared a transferrin 
(Tf) -bearing generation 3- diaminobutyric polypropylenimine dendrimer (DAB-Tf), able to 
increase the cellular uptake and gene expression of DNA by cancer cells overexpressing 
transferrin receptors compared to non-targeted delivery systems, in vitro and in vivo [14]. 
Importantly, the treatment was well tolerated by the animals, with no apparent signs of 
toxicity.  
Building on this study, we now would like to investigate if this Tf-bearing gene delivery 
system could improve the delivery of DNA to the brain, in vitro and in vivo following 
intravenous administration.  
 
 
 
2. Materials and methods 
2.1. Cell lines and reagents 
Human holo-transferrin, generation 3- diaminobutyric polypropylenimine dendrimer (DAB), 
dimethylsuberimidate and all other chemicals and reagents that are not specifically 
mentioned below were obtained from Sigma Aldrich (Poole, UK). The expression plasmids 
HQFRGLQJ ȕ-JDODFWRVLGDVH S&09VSRUWȕ-galactosidase) and tdTomato (pCMV-tdTomato) 
were  respectively purchased from Invitrogen (Paisley, UK) and Clontech (Mountain View, 
CA). They were propagated in E. coli and purified using an Endotoxin-free Giga Plasmid 
Kit (Qiagen, Hilden, Germany). Vectashield® PRXQWLQJ PHGLXP ZLWK ƍ-diamidino-2-
phenylindole (DAPI) came from Vector Laboratories (Peterborough, UK). Passive lysis 
buffer, Label IT® Cy3- and fluorescein- Nucleic Acid Labeling kits were respectively 
obtained from Promega (Southampton, UK) and Cambridge Biosciences (Cambridge, UK). 
bEnd.3 murine brain capillary endothelial cell line was purchased from LGC Standards 
(Teddington, UK), while cell culture media were obtained from Invitrogen (Paisley, UK).  
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2.2. Synthesis and characterization of transferrin- bearing DAB dendrimer 
Transferrin (Tf) was conjugated to generation 3- diaminobutyric polypropylenimine 
dendrimer (DAB) by using dimethylsuberimidate (DMSI) as a cross-linking agent, as 
previously reported [14, 15]. DAB (24 mg) was added to transferrin (6 mg) and 
dimethylsuberimidate (12 mg) in triethanolamine HCl buffer (pH 7.4, 2 mL). The reaction 
took place for 2 h at 25 oC whilst stirring. The conjugate was purified by size exclusion 
chromatography using a Sephadex G75 column and freeze-dried. The conjugation of Tf to 
DAB was assessed by 1H NMR spectroscopy using an Oxford NMR AS 400 spectrometer 
(Jeol, Peobody, MA).  
 
2.3. In vitro biological characterization 
2.3.1. Cell culture  
Immortalized bEnd.3 cells overexpressing Tf receptors were grown as monolayers in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine 
serum, 1% (v/v) L-glutamine and 0.5% (v/v) penicillin-streptomycin. Cells were cultured at 
37oC in a humid atmosphere of 5% carbon dioxide. 
 
2.3.2. Cellular uptake  
Imaging of the cellular uptake of the DNA carried by DAB-Tf was carried out using 
HSLIOXRUHVFHQFHPLFURVFRS\/DEHOLQJRI WKHȕ-galactosidase-encoding plasmid DNA with 
the fluorescent probe Cy3 was performed using a Label IT® Cy3 Nucleic Acid Labeling kit, 
as described by the manufacturer. bEnd.3 cells were seeded on coverslips in 6-well plates 
(104 cells/ well) and grown at 37oC for 72 h. They were then incubated for different 
durations (15, 30, 45, 60, 120, 240 min) with Cy3-labeled DNA (2.5 µg DNA / well) 
complexed to DAB-Tf at the dendrimer: DNA weight ratio of 10:1. The cells were then 
washed three times with PBS and fixed with methanol for 10 min. Upon staining of the 
nuclei with DAPI, the cells were examined using an E600FN Upright Epifluorescence 
microscope (Nikon, Tokyo, Japan). DAPI was excited with the 405 nm laser line 
(bandwidth: 415-491nm), whereas Cy3 was excited with the 543 nm laser line (bandwidth: 
550-620 nm). 
Once the treatment duration allowing maximal DNA uptake was determined, a similar 
procedure was performed to compare the cellular uptake of Cy3-ODEHOHG'1$ȝJwell) 
complexed to DAB-Tf and DAB (dendrimer: DNA weight ratios respectively of 10:1 and 5:1 
[14, 16] during the optimized treatment duration. Control samples were treated with naked 
DNA or remained untreated. 
 
Quantification of cellular uptake was performed using flow cytometry. Labeling of plasmid 
DNA with the fluorescent probe fluorescein was performed using a Label IT® Fluorescein 
Nucleic Acid Labeling kit, as described by the manufacturer. bEnd3 cells were grown in 6-
well plates (1.6 x 105 cells / well) at 37 °C for 72 h.  The cells were then treated with 
fluorescein-labeled DNA (5 µg DNA / well), alone or complexed to DAB-Tf and DAB 
(dendrimer: DNA weight ratios respectively of 10:1 and 5:1). Untreated cells served as a 
negative control. After 2 h incubation with the treatments, single cell suspensions were 
prepared, washed (2 mL PBS pH 7.4 per well) and pelleted (378 g for 8 min) 3 times, 
before being analyzed using a FACSCanto® flow cytometer (BD, Franklin Lakes, NJ). Ten 
thousand cells (gated events) were counted for each sample. Their mean fluorescence 
intensity was analyzed with FACSDiva® software (BD, Franklin Lakes, NJ).  
 
2.3.3. Mechanisms of cellular uptake of DNA complexed to DAB-Tf dendriplex 
The mechanisms involved in the cellular uptake of DNA complexed to DAB-Tf dendriplex 
were investigated by treatment with uptake inhibitors and escalating concentrations of free 
Tf. Cells were seeded and grown as described above. After removal of the medium, they 
were then pre-treated with phenylarsine oxide (10 µmol/L), filipin (5 µg/mL), colchicine (10 
µmol/L), poly-L-lysine (400 µg/mL) and various concentrations of free Tf ranging from 2.5 
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to 20 µmol/L for 10 min at 37oC. The cells were then treated with fluorescein-labeled DNA 
(respectively 2.5 and 5 ȝJwell for qualitative and quantitative analysis) complexed to DAB-
Tf for 2h, before being washed and processed for fluorescence microscopy and flow 
cytometer analysis as described above. 
 
2.3.4. In vitro transfection 
Transfection efficacy of the DNA carried by DAB-Tf dendrimer was assessed with a 
SODVPLG'1$HQFRGLQJȕ-JDODFWRVLGDVHS&09ȕJDOXVLQJDȕ-galactosidase transfection 
assay. bEnd.3 cells were seeded at a density of 2 000 cells/well in 96-well plates (n=15). 
After 72 h incubation, the cells were treated with the DAB-Tf dendriplex at the dendrimer: 
DNA weight ratio of 10:1, which has previously been shown to give the highest transfection 
on other cancer cell lines [14, 15]. DNA concentration (10 µg/mL) was kept constant for all 
the formulations tested. Naked DNA served as a negative control, DAB-DNA (dendrimer: 
DNA weight ratio 5:1) served as a positive control. After 72 h incubation, cells were lysed 
with 1X passive lysis buffer (PLB) (50 µL/well) for 20 min. The cell lysates were 
subsequently analyzed IRUȕ-galactosidase expression. Briefly, 50 µL of the assay buffer (2 
P0 PDJQHVLXP FKORULGH  P0 PHUFDSWRHWKDQRO  PJP/ Ƞ-nitrophenol-ȕ-
galactopyranoside, 200 mM sodium phosphate buffer, pH 7.3) were added to each well 
containing the lysates. After 2 h incubation at 37oC, the absorbance of the samples was 
read at 405 nm with a Multiscan Ascent® plate reader (Thermo Scientific, Waltham, MA). 
 
2.4. In vivo study 
2.4.1. Animals  
Female BALB/c mice were housed in groups of five at 19°C to 23°C with a 12-h light-dark 
cycle. They were fed a conventional diet (Rat and Mouse Standard Expanded, B&K 
Universal, Grimston, UK) with mains water ad libitum. The in vivo experiments described 
below were approved by the local ethics committee and performed in accordance with the 
UK Home Office regulations. 
 
2.4.2. Biodistribution of gene expression 
The biodistribution of gene expression was visualized by bioluminescence imaging, using 
an IVIS Spectrum® (PerkinElmer, Waltham, MA).  
To determinate the treatment duration leading to the highest gene expression, female 
BALB/c mice (n= 3, initial mean weight: 20 g) were injected intravenously with a single 
dose of DAB-Tf carrying luciferase expression plasmid (50 µg of DNA). They were then 
intraperitoneally injected with the luciferase substrate D-luciferin (150 mg/kg body weight) 
after various treatment durations and anaesthetized by isoflurane inhalation. Light 
emission was measured 10 min after injection of the D-luciferin solution, for 2 min, using 
Living Image® software (PerkinElmer, Waltham, MA). The resulting pseudo-color images 
represent the spatial distribution of photon counts within the animal. Identical illumination 
settings were used for acquiring all images [17]. 
A similar procedure was then performed at the optimum treatment duration to compare the 
distribution of gene expression resulting from the single intravenous injection of DAB-Tf 
and DAB dendriplexes encoding luciferase (50 µg of DNA). 
 
Biodistribution of gene expression was also quantified using a ȕ-galactosidase reporter 
gene expression assay. Groups of mice (n= 5) were injected intravenously with a single 
dose of DAB-Tf and DAB dendriplexes encoding luciferase (50 µg of DNA). They were 
sacrificed 24 h after injection and their organs were removed, frozen in liquid nitrogen, 
EHIRUHEHLQJDQDO\]HGIRUWKHLUȕ-galactosidase levels as previously described [18]. 
 
2.4.3. Distribution of gene expression within the brain 
Distribution of gene expression within the brain was qualitatively assessed by fluorescence 
microscopy imaging of the brain sections of mice treated with DAB-Tf dendriplex encoding 
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tdTomato. Mice were intravenously injected with a single dose of DNA encoding tdTomato, 
naked or complexed to DAB-Tf and DAB dendrimers (50 µg of DNA). They were sacrificed 
24 h after injection and their brains were removed, fixed in a solution of 10% formalin for 
48h. Following fixation, the brains were dehydrated through an ethanol gradient for 8h30, 
cleared in xylene for 2h30, before being embedded in paraffin wax. Coronal sections were 
cut at a thickness of 4 µm in different brain areas (anterior, median and posterior) and left 
in a 37oC oven overnight before being stained with hematoxylin and eosin (H&E) 
according to standard procedures. The brain sections were then examined using an 
E600FN Upright Epifluorescence microscope. Positivity for tdTomato expression in the 
brain was assessed at an excitation wavelength of 554 nm and emission wavelength of 
581 nm.   
 
2.5. Statistical Analysis 
Results were expressed as means ± standard error of the mean (S.E.M). Statistical 
significance was assessed by one-way analysis of variance (ANOVA) and Tukey multiple 
comparison post-test (Minitab® software, State College, PE). Differences were considered 
statistically significant for P values lower than 0.05.  
 
 
 
3. Results and discussion 
3.1. In vitro biological characterization 
3.1.1. Cellular uptake  
The uptake of Cy3-labeled DNA complexed to DAB-Tf by bEnd.3 cells was qualitatively 
confirmed by epifluorescence microscopy. Cy3-labeled DNA was disseminated in the 
cytoplasm from as early as 15 min after the start of the treatment. Following various 
treatment durations, the DNA uptake in cells appeared to be most pronounced after 
treatment with DAB-Tf dendriplex incubated with the cells for 2 h (Fig. 1).  
 
 
 
Figure 1. Epifluorescence microscopy imaging of the cellular uptake of Cy3- labeled DNA 
(2.5 µg/ well) complexed with DAB-Tf, after incubation for 15 min, 30 min, 45 min, 1 h, 2 h 
or 4 h with bEnd.3 cells (Blue: nuclei stained with DAPI (excitation: 405 nm, laser line 
bandwidth: 415-491 nm), green: Cy3-labeled DNA (excitation: 543 nm, laser line 
bandwidth: 550-620 nm) (Bar: 10 µm).  
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We then evaluated the cellular uptake of Cy3-labeled DNA either administered as 
complexed to DAB-Tf and DAB, or as a solution, following 2 h incubation (Fig. 2). The 
treatment of the cells with DAB-Tf dendriplex resulted in a pronounced DNA uptake in the 
cytoplasm of the cells. By contrast, cells treated with DAB dendriplex or DNA solution did 
not show any Cy3-derived fluorescence, highlighting the need of a targeted delivery 
system to carry DNA to bEnd.3 cells. The diffuse Cy3-derived fluorescence may be due to 
the homogeneous distribution of the fluorescently-labeled DNA in the cytoplasm following 
the escape of the DAB-Tf dendriplex from the endosomes and the release of the DNA from 
its dendritic carrier. 
These results were quantitatively confirmed by flow cytometry (Fig. 3). Cellular 
fluorescence was highest following treatment with DAB-Tf dendriplex (7682 ± 355 arbitrary 
units (a.u.)). It was respectively about 1.4-fold and 2.3-fold higher than the cellular 
fluorescence observed following treatment with DAB dendriplex (5531 ± 530 a. u.) and 
DNA solution (3370 ± 199 a. u.).  
 
 
 
 
 
 
Figure 2. Epifluorescence microscopy imaging of the cellular uptake of Cy3- labeled DNA 
(2.5 µg/ well) either complexed with DAB-Tf, DAB or in solution, after incubation for 2 
hours with bEnd.3 cells (Blue: nuclei stained with DAPI (excitation: 405 nm, laser line 
bandwidth: 415-491 nm), green: Cy3-labeled DNA (excitation: 543 nm, laser line 
bandwidth: 550-620 nm) (Bar: 10 µm).  
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Figure 3. Flow cytometry quantification of the cellular uptake fluorescein- labeled DNA 
(2.5 µg/ well) either complexed with DAB-Tf, DAB or in solution, after incubation for 2 
hours with bEnd.3 cells (n=15) * : P <0.05 compared with DAB-Tf-DNA. 
 
 
In this study, we successfully demonstrated that the conjugation of Tf on DAB improved 
DNA uptake by bEnd.3 murine brain capillary endothelial cells, compared to control 
dendriplex and naked DNA treatments. Tf receptor-mediated uptake of DNA has been 
widely studied on cancer cell lines and brain capillary endothelial cells [11, 14, 15, 19-30]. 
Although the differences between treatments were less pronounced in our study, our 
results were in accordance with previous data obtained by Ko and colleagues [24], who 
revealed that the uptake of TfR-targeting biotinylated PEG-stabilized liposomes 
encapsulating PEI/ oligodeoxynucleotide was about 3-fold higher compared to that of non-
targeted nanoparticles, in bEnd.5 mouse brain endothelial cell line. This outcome was also 
in line with our previous studies, in which we demonstrated that the conjugation of Tf to 
DAB increased the DNA uptake by T98G glioblastoma, PC-3M-luc-C6, DU145 and LNCaP 
prostate cells overexpressing Tf receptors [14, 19].  
 
3.1.2. Mechanisms of cellular uptake of DNA complexed to DAB-Tf dendriplex 
Pre-treatment of the bEnd.3 cells with various concentrations of free Tf significantly 
decreased the cellular uptake of fluorescein-labeled DNA complexed to DAB-Tf with 
increasing concentrations of free Tf, to reach a plateau at Tf concentrations higher than 
12.5 µM (Fig. 4 and 5). At a Tf concentration of 20 µM, the cellular uptake of fluorescently-
labeled DNA was 3.8-fold lower than that observed with DAB-Tf dendriplex without pre-Tf 
treatment (respectively 2010 ± 122 a. u. and  7682 ± 355 a. u.).  
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Figure 4. Epifluorescence microscopy imaging of the bEnd.3 cellular uptake of Cy3- 
labeled DNA (2.5 µg/ well) complexed with DAB-Tf, following pre-treatment with various 
concentrations of free Tf (ranging from 2.5 µM to 20 µM). (Blue: nuclei stained with DAPI 
(excitation: 405 nm, laser line bandwidth: 415-491 nm), green: Cy3-labeled DNA 
(excitation: 543 nm, laser line bandwidth: 550-620 nm) (Bar: 10 µm).  
 
Figure 5. Flow cytometry quantification of the bEnd.3 cellular uptake of fluorescein- 
labeled DNA (2.5 µg/ well) complexed with DAB-Tf, following pre-treatment with various 
concentrations of free Tf (ranging from 2.5 µM to 20 µM) (n=15), * : P <0.05 compared with 
DAB-Tf-DNA. 
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The cellular uptake of fluorescein-labeled DNA complexed to DAB-Tf was also partially 
inhibited by phenylarsine oxide, filipin, colchicine and poly-L-lysine (Fig. 6 and 7). 
Colchicine and phenylarsine oxide caused the most significant inhibition, with a cellular 
uptake respectively decreased by 2.3-fold and 2.1-fold compared to that observed with 
DAB-Tf dendriplex without inhibitory treatment (respectively 3316 ± 251 a. u. and 3614 ± 
140 a.u. following pre-treatment with colchicine and phenylarsine oxide). Filipin and poly-L-
Lysine appear to be less effective inhibitors, leading to a cellular uptake decreased by 
respectively 1.7-fold and 1.3-fold compared to DAB-Tf dendriplex without pre-treatment 
(respectively 4532 ± 201 a. u. and 5974 ± 192 a.u. following pre-treatment with filipin and 
poly-L-Lysine).  
These inhibitors act on various endocytic mechanisms on the BBB. Phenylarsine oxide is 
an inhibitor of clathrin-mediated endocytosis (which is a requisite for receptor-mediated 
endocytosis) [31]. Filipin is known to block the caveolae-mediated process in non-specific 
adsorptive endocytosis [32]. Colchicine inhibits macropinocytosis [33], which provides non-
specific endocytosis of macromolecules, whereas cationic poly-L-Lysine can inhibit the 
uptake of cationic delivery systems. 
The cellular uptake of DNA complexed to DAB-Tf was therefore related to endocytosis 
processes, including clathrin-mediated endocytosis, macropinocytosis, and to a lesser 
extent caveolae-mediated endocytosis. The zeta potential of DAB-Tf dendriplex was 
slightly cationic (1.03 mV) [14], which limited the possible inhibitory role of poly-L-lysine. 
These results suggested that both receptor- and adsorptive-mediated mechanisms might 
contribute to the cellular uptake of DNA complexed to DAB-Tf.  
Increasing amounts of Tf could significantly inhibit the cellular uptake of DNA complexed to 
DAB-Tf, suggesting that the Tf receptor-mediated mechanism might be the main 
mechanism of cellular internalization of DNA complexed to DAB-Tf.  
 
 
 
 
 
 
Figure 6. Epifluorescence microscopy imaging of the bEnd.3 cellular uptake of Cy3- 
labeled DNA (2.5 µg/ well) complexed with DAB-Tf, following pre-treatment with various 
FHOOXODUXSWDNHLQKLELWRUVSKHQ\ODUVLQHR[LGH³3K$V2´ILOLSLQ³)LO´colchicine (³&ROFK´
and poly-L-O\VLQH ³3/\V´ (Blue: nuclei stained with DAPI (excitation: 405 nm, laser line 
bandwidth: 415-491 nm), green: Cy3-labeled DNA (excitation: 543 nm, laser line 
bandwidth: 550-620 nm) (Bar: 10 µm).  
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Figure 7. Flow cytometry quantification of the bEnd.3 cellular uptake of fluorescein- 
labeled DNA (2.5 µg/ well) complexed with DAB-Tf, following pre-treatment with various 
cellular uptake inhibitors: SKHQ\ODUVLQHR[LGH³3K$V2´ILOLSLQ³)LO´colchicine (³&ROFK´
and poly-L-O\VLQH³3/\V´Q=15), * : P <0.05 compared with DAB-Tf-DNA. 
 
3.1.3. In vitro transfection 
The conjugation of Tf to DAB dendriplex led to an increased transfection compared to 
unconjugated DAB dendriplex on bEnd.3 cells (Fig. 8). Gene expression following 
treatment with DAB-Tf dendriplex was 1.3-fold higher than following treatment with DAB 
dendriplex (3.79x10-3 ± 0.23x10-3 U/mL and 2.85x10-3 ± 0.21x10-3 U/mL respectively for 
DAB-Tf and DAB dendriplexes).  
The treatment of bEnd.3 cells with Tf-bearing and DAB dendriplexes resulted in an 
increase in gene expression by about 4.3-fold and 3.3-fold respectively, compared to that 
observed following treatment with naked DNA (0.87x10-3 ± 0.01x10-3 U/mL). The cells 
treated with naked DNA did not show any significant transfection increase compared to 
untreated cells.  
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Figure 8. Transfection efficacy of DAB-Tf and DAB dendriplexes in bEnd.3 cells. DAB-Tf 
and DAB dendriplexes were dosed at their optimal dendrimer: DNA ratio of 10:1 and 5:1 
respectively. Results are expressed as the mean ± SEM of three replicates (n=15). * : P 
<0.05 compared with DAB-Tf-DNA. 
 
The enhanced ȕ-gal expression following DAB-Tf dendriplex treatment most likely resulted 
from the improved cellular uptake observed with this treatment. Both increases were of the 
same magnitude (1.4-fold for cellular uptake, 1.3-fold for gene expression compared to 
non-targeted DAB dendriplex treatment). These transfection results were in line with those 
described in the literature. For example, Huang and colleagues reported that the luciferase 
expression in brain capillary endothelial cells treated with Tf-bearing PEG-PAMAM 
dendriplex was 1.8-fold of that obtained with PAMAM dendriplex and PEG-PAMAM 
dendriplex [26]. In our previous experiments, the conjugation of Tf on DAB dendriplex 
already led to similar  increases of gene expression, by 1.3-fold on both T98G and PC-3 
cells, and by 2.2-fold on A431 cells, compared to that observed following treatment with 
DAB dendriplex [ 14, 19].  
 
3.2. In vivo study 
Distribution of gene expression following intravenous injection of DAB-Tf dendriplex 
encoding luciferase was first qualitatively assessed by luminescence imaging, at various 
treatment durations. Gene expression appeared to be mainly located in the brain of the 
mice. The highest gene expression level was found 24 h following injection of the 
treatment (Fig. 9). 
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Figure 9. Bioluminescence imaging of gene expression after intravenous administration of 
DAB-Tf dendriplex (50 µg DNA administered). The mice were imaged using the IVIS 
Spectrum at various durations after injection of the treatment. The scale indicates surface 
radiance (photons/s/cm2/steradian). 
 
 
Gene expression following administration of DAB-Tf dendriplex was then compared to that 
observed following administration of DAB dendriplex and DNA only, 24 h after 
administration of the treatments. The level of gene expression in the brain appeared to be 
highest following treatment with DAB-Tf dendriplex (Fig. 10). In addition, luciferase 
expression appeared to be very limited in organs other than brain. This might be explained 
by the threshold of the technique that probably allowed only the most intensely 
luminescent tissues to be analyzed. 
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Figure 10. Bioluminescence imaging of gene expression after intravenous administration 
of DAB-Tf and DAB dendriplexes (50 µg DNA administered). (Controls: DNA solution, 
untreated cells). The mice were imaged using the IVIS Spectrum 24 h after injection of the 
treatments. The scale indicates surface radiance (photons/s/cm2/steradian). 
 
 
These results were confirmed by quantification of gene expression in the major organs of 
the mice. The intravenous administration of DAB dendriplex led to gene expression mainly 
in the brain (16.7 ± 7.6 P8ȕ-galactosidase per organ) DQGWKHVSOHHQP8ȕ-
galactosidase per organ), followed by the kidneys (12.1 ± 3.6 P8 ȕ-galactosidase per 
organ) and then the lung (6.6 ± 2.6 P8ȕ-galactosidase per organ) (Fig. 11).  
By contrast, the conjugation of Tf to DAB significantly increased by more than 2-fold the 
gene expression in the brain (37.3 P8ȕ-galactosidase for DAB-Tf dendriplex), while 
there was very little ȕ-galactosidase detected in the liver, the lung and the spleen. In the 
kidneys and the heart, gene expression reached similar levels to what was observed 
following treatment with DAB dendriplex (10.5 ± 6.1 mU and 12.1 ± 3.6 P8 ȕ-
galactosidase per organ in the kidneys for respectively DAB-Tf dendriplex and DAB 
dendriplex, 2.5 ± 1.6 mU and 0.9 ± 1.6 P8ȕ-galactosidase in the heart for respectively 
DAB-Tf dendriplex and DAB dendriplex). Ǻ-galactosidase gene expression in the brain 
was at least 3-fold higher than in any peripheral organs tested in this study. 
The amount of Tf injected as DAB-Tf was much higher than the endogenous amount of Tf 
in the plasma (2.68 µg, corresponding to an endogenous plasma concentration of 25 µM 
[34], which limited the risk of competition for binding to the TfR. 
:H KDYH FKRVHQ WR XVH D ȕ-galactosidase expression assay for quantifying gene 
expression in the organs, as the spectrofluorimetric quantification of the reaction product 
7-hydroxy-9H-(1, 3-dichloro-9, 9-dimethyl-acridin-2-one (DDAO) in the red part of the 
spectrum avoided interferences from hemoglobin which hamper many in vivo 
quantification assays [18, 35]. 
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Figure 11. Biodistribution of gene expression after a single intravenous administration of 
DAB-Tf and DAB dendriplexes (50 µg DNA administered). Results were expressed as 
PLOOLXQLWV ȕ-galactosidase per organ (n=5). * : P <0.05 compared with DAB-Tf-DNA for 
each organ. 
 
 
Within the brain, gene expression was the highest following administration of DAB-Tf 
dendriplex (Fig. 12). It was homogenously distributed in the brain parenchyma in all the 
sections of the brain we observed, but did not appear to have reached the neurons and 
glial cells. By contrast, tdTomato gene expression was very limited in the brain following 
administration of DAB dendriplex. Some autofluorescence artefacts were visible in the 
brain treated with naked DNA or left untreated.   
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Figure 12. Epifluorescence microscopy imaging of the distribution of gene expression 
within the brain after a single intravenous injection of tdTomato- encoded DNA (50 µg) 
either complexed with DAB-Tf, DAB or in solution (Magnification: x 60).  
 
 
This communication presents evidence that DAB-Tf dendriplex led to improved gene 
expression in the brain following intravenous administration. To our knowledge, it is the 
first time that the intravenous administration of a Tf-bearing non-viral delivery system 
resulted in such intense effects.  
Other groups have already demonstrated gene transfer capabilities of Tf-bearing and TfR-
targeting gene delivery systems following intravenous administration, but with much 
smaller gene expression in the brain and much larger non-specific expression in other 
organs. For example, the intravenous administration of liposomes encapsulating 
polyethylenimine/ 32P- oligodeoxynucleotide polyplexes and conjugated to 8D3 anti-mouse 
Tf receptor monoclonal antibody, resulted in an increased brain uptake, but with the tracer 
activity being found mainly in liver, spleen and kidneys [24].  
Similar gene expression levels and tissue expression patterns were seen when lipoplexes 
encoding luciferase were conjugated with the OX26 anti-rat Tf receptor monoclonal 
antibody. Following 48 h after intravenous administration of this lipoplex, the exogenous 
gene was expressed in brain with levels as high as 0.2 pg/mg protein, but was also mainly 
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found in peripheral tissues such as liver, spleen and lung [36]. Another study using a 
similar lipoplex reported that the luciferase gene expression in brain was comparable to 
that of lung or spleen [22]. Similarly, the injection of 8D3-bearing PEGylated 
immunolipoplexes encoding ȕ-galactosidase also led to a similar pattern of distribution, 
with gene expression being found in the brain, but mostly in liver and spleen [20, 22].  
The differences in the biodistribution of gene expression may be explained by the targeting 
of different TfR and the use of Tf instead of anti-TfR antibodies as a targeting moiety. Both 
TfR1 and TfR2 are members of the Tf receptor family. TfR1 is expressed at low levels in 
most human tissues, but is highly expressed on the vascular endothelium of brain 
capillaries [7]. It is also expressed at levels up to 100-fold higher than those on normal 
cells on highly proliferative cells such as cancer cells [37], making this receptor a 
promising target for the delivery of therapeutics to the brain and cancer cells.  By contrast, 
WKHĮ-WUDQVFULSWSURGXFWRI7I5LVPRVWO\H[SUHVVHGRQKHSDWRF\WHVZKLOHLWVȕ-transcript 
is present on a wide range of tissues but at very low levels [38]. In addition, TfR1 has a 
much higher affinity for Tf than TfR2 (25-fold higher) [38], which is not the case for anti-TfR 
monoclonal antibodies. TfR1 would therefore be a more efficient target for transferrin-
mediated gene delivery to the brain or cancer cells. 
 
Previous studies using the dendrimer polyamidoamine (PAMAM) instead of DAB have 
shown that the gene expression of intravenously administered Tf-bearing PAMAM 
dendriplex was about 2-fold higher in the brain than that of non-targeted dendriplex. Gene 
expression of luciferase, however, was mainly found in heart and lung [26]. 
In a previous study done on tumor-bearing mice, we demonstrated that the intravenous 
administration of DAB dendrimer conjugated to transferrin (Tf), whose receptors are also 
overexpressed on cancer cells, resulted in gene expression mainly in the tumors after 
intravenous administration [14]. Thus, DAB-7IGHQGULPHUFRPSOH[HGWRD71)Į-encoding 
DNA led to a rapid and sustained tumor regression over one month, resulting in complete 
suppression of 90% of the tested A431 tumors and regression of the remaining 10% [14]. 
In this study, we wanted to investigate if the targeting properties of this dendrimer could 
lead to an enhanced delivery of DNA to the brain after intravenous administration, on mice 
without tumors. We demonstrated that this is indeed the case. 
 
In conclusion, we have demonstrated that transferrin-bearing DAB polypropylenimine 
dendrimer led to an increased gene expression in the brain, which was at least 3-fold 
higher than in any tested peripheral organs. Transferrin-bearing DAB dendrimer is 
therefore a highly promising delivery system for gene delivery to the brain and will be 
further investigated to optimize its therapeutic potential. 
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FIGURE CAPTIONS 
Figure 1. Epifluorescence microscopy imaging of the cellular uptake of Cy3- labeled DNA 
(2.5 µg/ well) complexed with DAB-Tf, after incubation for 15 min, 30 min, 45 min, 1 h, 2 h 
or 4 h with bEnd.3 cells (Blue: nuclei stained with DAPI (excitation: 405 nm, laser line 
bandwidth: 415-491 nm), green: Cy3-labeled DNA (excitation: 543 nm, laser line 
bandwidth: 550-620 nm) (Bar: 10 µm).  
 
Figure 2. Epifluorescence microscopy imaging of the cellular uptake of Cy3- labeled DNA 
(2.5 µg/ well) either complexed with DAB-Tf, DAB or in solution, after incubation for 2 
hours with bEnd.3 cells (Blue: nuclei stained with DAPI (excitation: 405 nm, laser line 
bandwidth: 415-491 nm), green: Cy3-labeled DNA (excitation: 543 nm, laser line 
bandwidth: 550-620 nm) (Bar: 10 µm).  
 
Figure 3. Flow cytometry quantification of the cellular uptake of fluorescein- labeled DNA 
(2.5 µg/ well) either complexed with DAB-Tf, DAB or in solution, after incubation for 2 
hours with bEnd.3 cells (n=15) * : P <0.05 compared with DAB-Tf-DNA. 
 
Figure 4. Epifluorescence microscopy imaging of the bEnd.3 cellular uptake of Cy3- 
labeled DNA (2.5 µg/ well) complexed with DAB-Tf, following pre-treatment with various 
concentrations of free Tf (ranging from 2.5 µM to 20 µM). (Blue: nuclei stained with DAPI 
(excitation: 405 nm, laser line bandwidth: 415-491 nm), green: Cy3-labeled DNA 
(excitation: 543 nm, laser line bandwidth: 550-620 nm) (Bar: 10 µm).  
 
Figure 5. Flow cytometry quantification of the bEnd.3 cellular uptake of fluorescein- 
labeled DNA (2.5 µg/ well) complexed with DAB-Tf, following pre-treatment with various 
concentrations of free Tf (ranging from 2.5 µM to 20 µM) (n=15), * : P <0.05 compared with 
DAB-Tf-DNA. 
 
Figure 6. Epifluorescence microscopy imaging of the bEnd.3 cellular uptake of Cy3- 
labeled DNA (2.5 µg/ well) complexed with DAB-Tf, following pre-treatment with various 
cellular uptake inhibitorsSKHQ\ODUVLQHR[LGH³3K$V2´ILOLSLQ³)LO´colchicine (³&ROFK´
and poly-L-O\VLQH ³3/\V´ %OXe: nuclei stained with DAPI (excitation: 405 nm, laser line 
bandwidth: 415-491 nm), green: Cy3-labeled DNA (excitation: 543 nm, laser line 
bandwidth: 550-620 nm) (Bar: 10 µm).  
 
Figure 7. Flow cytometry quantification of the bEnd.3 cellular uptake of fluorescein- 
labeled DNA (2.5 µg/ well) complexed with DAB-Tf, following pre-treatment with various 
cellular uptake inhibitors: SKHQ\ODUVLQHR[LGH³3K$V2´ILOLSLQ³)LO´colchicine (³&ROFK´
and poly-L-O\VLQH³3/\V´Q  : P <0.05 compared with DAB-Tf-DNA. 
 
Figure 8. Transfection efficacy of DAB-Tf and DAB dendriplexes in bEnd.3 cells. DAB-Tf 
and DAB dendriplexes were dosed at their optimal dendrimer: DNA ratio of 10:1 and 5:1 
respectively. Results are expressed as the mean ± SEM of three replicates (n=15). * : P 
<0.05 compared with DAB-Tf-DNA. 
 
Figure 9. Bioluminescence imaging of gene expression after intravenous administration of 
DAB-Tf dendriplex (50 µg DNA administered). The mice were imaged using the IVIS 
Spectrum at various durations after injection of the treatment. The scale indicates surface 
radiance (photons/s/cm2/steradian). 
 
Figure 10. Bioluminescence imaging of gene expression after intravenous administration 
of DAB-Tf and DAB dendriplexes (50 µg DNA administered). (Controls: DNA solution, 
untreated cells). The mice were imaged using the IVIS Spectrum 24 h after injection of the 
treatments. The scale indicates surface radiance (photons/s/cm2/steradian). 
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Figure 11. Biodistribution of gene expression after a single intravenous administration of 
DAB-Tf and DAB dendriplexes (50 µg DNA administered). Results were expressed as 
PLOOLXQLWV ȕ-galactosidase per organ (n=5). * : P <0.05 compared with DAB-Tf-DNA for 
each organ. 
 
Figure 12. Epifluorescence microscopy imaging of the distribution of gene expression 
within the brain after a single intravenous injection of tdTomato- encoded DNA (50 µg) 
either complexed with DAB-Tf, DAB or in solution (Magnification: x60).  
 
 
 
